| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes, Cytotoxic | 38 | 2019 | 520 | 5.680 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 39 | 2024 | 1192 | 5.060 |
Why?
|
| Virus Diseases | 21 | 2024 | 291 | 4.830 |
Why?
|
| T-Lymphocytes | 43 | 2025 | 1759 | 4.720 |
Why?
|
| Adoptive Transfer | 14 | 2020 | 241 | 2.490 |
Why?
|
| Immunotherapy, Adoptive | 32 | 2025 | 898 | 2.440 |
Why?
|
| Antigens, Neoplasm | 20 | 2025 | 403 | 2.200 |
Why?
|
| Adenoviridae | 22 | 2023 | 596 | 1.930 |
Why?
|
| Epstein-Barr Virus Infections | 12 | 2023 | 293 | 1.840 |
Why?
|
| Herpesvirus 4, Human | 28 | 2023 | 675 | 1.620 |
Why?
|
| Immunity, Cellular | 6 | 2023 | 204 | 1.620 |
Why?
|
| Adenoviridae Infections | 7 | 2013 | 69 | 1.600 |
Why?
|
| Immunotherapy | 13 | 2024 | 748 | 1.430 |
Why?
|
| CD8-Positive T-Lymphocytes | 14 | 2024 | 449 | 1.260 |
Why?
|
| Epitopes, T-Lymphocyte | 12 | 2020 | 130 | 1.250 |
Why?
|
| Immunocompromised Host | 9 | 2024 | 308 | 1.210 |
Why?
|
| Antigens, Viral | 14 | 2020 | 439 | 1.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2024 | 503 | 1.150 |
Why?
|
| Transplantation, Homologous | 16 | 2024 | 648 | 1.130 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 571 | 1.030 |
Why?
|
| Lymphocyte Transfusion | 3 | 2021 | 58 | 0.970 |
Why?
|
| Viruses | 2 | 2018 | 126 | 0.930 |
Why?
|
| Antigen-Presenting Cells | 10 | 2014 | 133 | 0.930 |
Why?
|
| Hematologic Neoplasms | 5 | 2015 | 294 | 0.920 |
Why?
|
| Receptors, Antigen, T-Cell | 11 | 2025 | 499 | 0.920 |
Why?
|
| Graft vs Leukemia Effect | 3 | 2021 | 36 | 0.900 |
Why?
|
| Cell- and Tissue-Based Therapy | 9 | 2024 | 165 | 0.890 |
Why?
|
| Graft vs Host Disease | 11 | 2024 | 621 | 0.870 |
Why?
|
| Leukocytes, Mononuclear | 7 | 2020 | 356 | 0.850 |
Why?
|
| Lymphocyte Activation | 15 | 2019 | 686 | 0.850 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 82 | 0.810 |
Why?
|
| Dendritic Cells | 11 | 2017 | 448 | 0.810 |
Why?
|
| Cytomegalovirus | 13 | 2019 | 263 | 0.800 |
Why?
|
| Salvage Therapy | 2 | 2021 | 201 | 0.780 |
Why?
|
| Lymphoma | 7 | 2021 | 331 | 0.700 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2021 | 127 | 0.670 |
Why?
|
| Viral Matrix Proteins | 12 | 2018 | 110 | 0.670 |
Why?
|
| Humans | 107 | 2025 | 132334 | 0.660 |
Why?
|
| Adenovirus Infections, Human | 3 | 2010 | 57 | 0.650 |
Why?
|
| T-Cell Antigen Receptor Specificity | 7 | 2021 | 56 | 0.610 |
Why?
|
| Cytotoxicity, Immunologic | 11 | 2025 | 266 | 0.600 |
Why?
|
| Tumor Microenvironment | 5 | 2024 | 688 | 0.600 |
Why?
|
| Receptors, Interleukin-7 | 3 | 2025 | 24 | 0.570 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 203 | 0.550 |
Why?
|
| Epitopes | 5 | 2018 | 437 | 0.550 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2017 | 12 | 0.550 |
Why?
|
| Respirovirus Infections | 1 | 2017 | 20 | 0.550 |
Why?
|
| DNA Viruses | 2 | 2017 | 32 | 0.540 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 49 | 0.530 |
Why?
|
| Metapneumovirus | 1 | 2017 | 52 | 0.530 |
Why?
|
| Pancreatic Neoplasms | 5 | 2025 | 728 | 0.520 |
Why?
|
| Herpesviridae Infections | 2 | 2018 | 146 | 0.500 |
Why?
|
| Graft Survival | 1 | 2018 | 475 | 0.490 |
Why?
|
| Neoplasms | 6 | 2022 | 2944 | 0.480 |
Why?
|
| Cytomegalovirus Infections | 4 | 2013 | 225 | 0.460 |
Why?
|
| Capsid Proteins | 2 | 2007 | 195 | 0.460 |
Why?
|
| Transplant Recipients | 3 | 2024 | 225 | 0.460 |
Why?
|
| Cell Culture Techniques | 8 | 2019 | 288 | 0.450 |
Why?
|
| Graft Rejection | 1 | 2018 | 560 | 0.440 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2014 | 9 | 0.430 |
Why?
|
| Cells, Cultured | 10 | 2012 | 3062 | 0.430 |
Why?
|
| Herpesvirus 6, Human | 2 | 2017 | 55 | 0.410 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 219 | 0.400 |
Why?
|
| Roseolovirus Infections | 1 | 2012 | 30 | 0.390 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2017 | 761 | 0.380 |
Why?
|
| Monocytes | 3 | 2012 | 345 | 0.380 |
Why?
|
| Virus Activation | 1 | 2012 | 85 | 0.380 |
Why?
|
| Interleukin-7 | 3 | 2025 | 50 | 0.370 |
Why?
|
| T-Lymphocyte Subsets | 4 | 2014 | 210 | 0.370 |
Why?
|
| Immunophenotyping | 9 | 2019 | 344 | 0.370 |
Why?
|
| Genetic Therapy | 7 | 2024 | 720 | 0.360 |
Why?
|
| Cell Line, Tumor | 18 | 2025 | 3697 | 0.360 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2015 | 461 | 0.350 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 4 | 2018 | 60 | 0.350 |
Why?
|
| Interleukin-12 | 2 | 2008 | 122 | 0.340 |
Why?
|
| Genetic Vectors | 8 | 2014 | 927 | 0.330 |
Why?
|
| Tissue Donors | 5 | 2021 | 508 | 0.330 |
Why?
|
| BK Virus | 3 | 2023 | 60 | 0.320 |
Why?
|
| Hodgkin Disease | 5 | 2014 | 305 | 0.320 |
Why?
|
| Antigen Presentation | 6 | 2024 | 117 | 0.310 |
Why?
|
| Neoplasm Proteins | 6 | 2025 | 701 | 0.310 |
Why?
|
| Liver Transplantation | 1 | 2018 | 1103 | 0.310 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2023 | 47 | 0.310 |
Why?
|
| DNA, Viral | 2 | 2009 | 492 | 0.310 |
Why?
|
| Genetic Engineering | 3 | 2019 | 164 | 0.300 |
Why?
|
| Adolescent | 16 | 2021 | 20552 | 0.300 |
Why?
|
| Child, Preschool | 13 | 2023 | 14851 | 0.300 |
Why?
|
| Stem Cell Transplantation | 2 | 2009 | 248 | 0.290 |
Why?
|
| Allografts | 2 | 2021 | 196 | 0.280 |
Why?
|
| Adult | 20 | 2024 | 31618 | 0.280 |
Why?
|
| Transgenes | 3 | 2014 | 336 | 0.270 |
Why?
|
| Male | 28 | 2024 | 65052 | 0.270 |
Why?
|
| Interferon-gamma | 6 | 2020 | 539 | 0.270 |
Why?
|
| Female | 28 | 2025 | 70786 | 0.270 |
Why?
|
| Child | 18 | 2023 | 25823 | 0.260 |
Why?
|
| Coculture Techniques | 5 | 2019 | 239 | 0.260 |
Why?
|
| Cross Reactions | 2 | 2004 | 190 | 0.260 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2014 | 225 | 0.260 |
Why?
|
| Leukemia, Myeloid | 2 | 2020 | 81 | 0.260 |
Why?
|
| Lymphocyte Depletion | 4 | 2012 | 125 | 0.250 |
Why?
|
| Recurrence | 7 | 2022 | 1458 | 0.250 |
Why?
|
| Immune System Diseases | 1 | 2006 | 52 | 0.250 |
Why?
|
| Young Adult | 7 | 2021 | 9945 | 0.240 |
Why?
|
| Cell Communication | 1 | 2007 | 187 | 0.240 |
Why?
|
| Leukemia | 3 | 2022 | 373 | 0.240 |
Why?
|
| Cell Proliferation | 10 | 2019 | 2512 | 0.240 |
Why?
|
| Immunologic Memory | 5 | 2019 | 199 | 0.230 |
Why?
|
| Transduction, Genetic | 7 | 2014 | 294 | 0.230 |
Why?
|
| Immunodominant Epitopes | 2 | 2017 | 52 | 0.230 |
Why?
|
| Flow Cytometry | 6 | 2012 | 806 | 0.230 |
Why?
|
| Th1 Cells | 3 | 2020 | 159 | 0.230 |
Why?
|
| Immunological Synapses | 1 | 2025 | 30 | 0.220 |
Why?
|
| Fetal Blood | 3 | 2010 | 174 | 0.220 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 61 | 0.220 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 2683 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2025 | 998 | 0.220 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 120 | 0.210 |
Why?
|
| Infant | 8 | 2023 | 13192 | 0.210 |
Why?
|
| DNA Virus Infections | 2 | 2017 | 22 | 0.210 |
Why?
|
| Cell Line | 8 | 2013 | 2730 | 0.210 |
Why?
|
| Middle Aged | 13 | 2024 | 28888 | 0.210 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 76 | 0.200 |
Why?
|
| Fas Ligand Protein | 1 | 2022 | 37 | 0.200 |
Why?
|
| Peptides | 7 | 2024 | 847 | 0.190 |
Why?
|
| Amino Acid Sequence | 6 | 2020 | 2673 | 0.190 |
Why?
|
| Animals | 20 | 2025 | 34989 | 0.190 |
Why?
|
| Mucin-1 | 3 | 2025 | 38 | 0.190 |
Why?
|
| Vaccination | 3 | 2023 | 1017 | 0.190 |
Why?
|
| Virus Latency | 2 | 2002 | 63 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 234 | 0.190 |
Why?
|
| Killer Cells, Natural | 2 | 2022 | 351 | 0.190 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 672 | 0.190 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2021 | 10 | 0.180 |
Why?
|
| Feasibility Studies | 5 | 2017 | 826 | 0.180 |
Why?
|
| HEK293 Cells | 5 | 2018 | 796 | 0.180 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 49 | 0.180 |
Why?
|
| Antiviral Agents | 5 | 2023 | 822 | 0.180 |
Why?
|
| Interleukin-4 | 2 | 2018 | 147 | 0.170 |
Why?
|
| Transplantation Immunology | 2 | 2012 | 45 | 0.170 |
Why?
|
| Prognosis | 5 | 2021 | 5009 | 0.170 |
Why?
|
| Single-Chain Antibodies | 2 | 2011 | 45 | 0.170 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 233 | 0.170 |
Why?
|
| Smallpox | 1 | 2020 | 11 | 0.170 |
Why?
|
| Cyclin A1 | 1 | 2020 | 4 | 0.160 |
Why?
|
| Monitoring, Immunologic | 1 | 2020 | 14 | 0.160 |
Why?
|
| Anemia | 1 | 2024 | 351 | 0.160 |
Why?
|
| Smallpox Vaccine | 1 | 2020 | 38 | 0.160 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2023 | 377 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1297 | 0.150 |
Why?
|
| Cytokines | 4 | 2019 | 1368 | 0.150 |
Why?
|
| Viral Load | 2 | 2018 | 410 | 0.150 |
Why?
|
| Blood Platelets | 2 | 2019 | 325 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1303 | 0.150 |
Why?
|
| Herpesvirus 3, Human | 1 | 2018 | 30 | 0.150 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2009 | 53 | 0.140 |
Why?
|
| Virus Replication | 2 | 2020 | 636 | 0.140 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 1205 | 0.140 |
Why?
|
| Membrane Glycoproteins | 2 | 2013 | 421 | 0.140 |
Why?
|
| Granzymes | 1 | 2017 | 48 | 0.140 |
Why?
|
| Herpesviridae | 1 | 2018 | 34 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 1347 | 0.140 |
Why?
|
| Treatment Outcome | 7 | 2024 | 13016 | 0.140 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 68 | 0.130 |
Why?
|
| Mice, SCID | 3 | 2014 | 604 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2023 | 6540 | 0.130 |
Why?
|
| Viremia | 1 | 2018 | 133 | 0.130 |
Why?
|
| Elephants | 1 | 2018 | 44 | 0.130 |
Why?
|
| HLA Antigens | 4 | 2012 | 220 | 0.130 |
Why?
|
| Peptide Fragments | 5 | 2013 | 799 | 0.130 |
Why?
|
| Lymphocyte Subsets | 1 | 2017 | 41 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2014 | 816 | 0.130 |
Why?
|
| Viral Proteins | 1 | 2018 | 358 | 0.130 |
Why?
|
| Adenocarcinoma | 1 | 2024 | 1018 | 0.130 |
Why?
|
| Adenoviruses, Human | 3 | 2017 | 97 | 0.130 |
Why?
|
| Epitope Mapping | 3 | 2013 | 83 | 0.120 |
Why?
|
| Gene Expression | 4 | 2017 | 1564 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 475 | 0.120 |
Why?
|
| Conserved Sequence | 2 | 2007 | 295 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2020 | 1454 | 0.120 |
Why?
|
| Myeloablative Agonists | 1 | 2015 | 20 | 0.120 |
Why?
|
| Antilymphocyte Serum | 1 | 2015 | 42 | 0.110 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 234 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 667 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2013 | 830 | 0.110 |
Why?
|
| Mice | 10 | 2025 | 18571 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 250 | 0.110 |
Why?
|
| Receptors, LDL | 1 | 2014 | 104 | 0.110 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 1577 | 0.110 |
Why?
|
| Caspase 9 | 1 | 2014 | 76 | 0.110 |
Why?
|
| Gene Transfer Techniques | 3 | 2010 | 350 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 217 | 0.110 |
Why?
|
| Cell Engineering | 1 | 2013 | 20 | 0.110 |
Why?
|
| Peptide Library | 2 | 2011 | 61 | 0.100 |
Why?
|
| Species Specificity | 1 | 2014 | 543 | 0.100 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2014 | 111 | 0.100 |
Why?
|
| Blood Donors | 2 | 2011 | 61 | 0.100 |
Why?
|
| Histocompatibility Testing | 2 | 2013 | 111 | 0.100 |
Why?
|
| Mutation | 2 | 2024 | 6248 | 0.100 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 300 | 0.100 |
Why?
|
| Flutamide | 1 | 2013 | 27 | 0.100 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2013 | 21 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 5405 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2011 | 195 | 0.100 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2013 | 31 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 210 | 0.100 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2013 | 63 | 0.100 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 198 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2018 | 3139 | 0.100 |
Why?
|
| CD28 Antigens | 2 | 2025 | 81 | 0.090 |
Why?
|
| Human papillomavirus 16 | 1 | 2013 | 97 | 0.090 |
Why?
|
| Aged | 6 | 2024 | 21379 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 95 | 0.090 |
Why?
|
| CD40 Ligand | 1 | 2012 | 64 | 0.090 |
Why?
|
| Brain Neoplasms | 2 | 2012 | 1409 | 0.090 |
Why?
|
| HLA-A Antigens | 3 | 2011 | 33 | 0.090 |
Why?
|
| Risk Factors | 2 | 2018 | 10910 | 0.090 |
Why?
|
| Molecular Sequence Data | 3 | 2005 | 3780 | 0.090 |
Why?
|
| Azacitidine | 1 | 2011 | 53 | 0.090 |
Why?
|
| Neuroblastoma | 1 | 2017 | 550 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 618 | 0.090 |
Why?
|
| Receptors, Antigen | 1 | 2011 | 33 | 0.090 |
Why?
|
| Neoplastic Stem Cells | 2 | 2011 | 348 | 0.090 |
Why?
|
| Tumor Escape | 2 | 2013 | 64 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 265 | 0.090 |
Why?
|
| Chills | 1 | 2010 | 6 | 0.090 |
Why?
|
| Home Infusion Therapy | 1 | 2010 | 6 | 0.090 |
Why?
|
| Oncolytic Virotherapy | 1 | 2012 | 89 | 0.090 |
Why?
|
| Nephritis, Interstitial | 1 | 2011 | 40 | 0.090 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2014 | 61 | 0.090 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2010 | 15 | 0.080 |
Why?
|
| Drugs, Investigational | 1 | 2010 | 24 | 0.080 |
Why?
|
| In Vitro Techniques | 3 | 2010 | 867 | 0.080 |
Why?
|
| B7-1 Antigen | 2 | 2007 | 12 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 387 | 0.080 |
Why?
|
| Leukemia, B-Cell | 1 | 2010 | 25 | 0.080 |
Why?
|
| Antigens | 1 | 2010 | 149 | 0.080 |
Why?
|
| Plasmids | 1 | 2010 | 459 | 0.080 |
Why?
|
| Antigens, CD34 | 1 | 2009 | 109 | 0.080 |
Why?
|
| Receptors, Virus | 1 | 2010 | 110 | 0.080 |
Why?
|
| CD3 Complex | 1 | 2009 | 92 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2011 | 168 | 0.080 |
Why?
|
| Stem Cells | 1 | 2014 | 732 | 0.080 |
Why?
|
| Retinoblastoma | 1 | 2010 | 113 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 4 | 2013 | 1047 | 0.070 |
Why?
|
| Interleukins | 1 | 2009 | 129 | 0.070 |
Why?
|
| Fever | 1 | 2010 | 312 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2013 | 815 | 0.070 |
Why?
|
| Cell Line, Transformed | 3 | 2014 | 161 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2012 | 374 | 0.070 |
Why?
|
| Receptor, ErbB-2 | 1 | 2011 | 549 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2019 | 1975 | 0.060 |
Why?
|
| Cell Survival | 2 | 2019 | 869 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2007 | 170 | 0.060 |
Why?
|
| Cell Separation | 3 | 2012 | 227 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 2064 | 0.060 |
Why?
|
| Virion | 2 | 2020 | 151 | 0.060 |
Why?
|
| K562 Cells | 3 | 2011 | 97 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2007 | 153 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2009 | 554 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 816 | 0.060 |
Why?
|
| Lymphocytes | 2 | 2023 | 365 | 0.060 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 26 | 0.060 |
Why?
|
| Cell Transformation, Viral | 1 | 2005 | 98 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2007 | 437 | 0.060 |
Why?
|
| Biomarkers | 2 | 2019 | 3389 | 0.060 |
Why?
|
| GPI-Linked Proteins | 2 | 2018 | 107 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 4695 | 0.060 |
Why?
|
| HLA-B Antigens | 1 | 2024 | 30 | 0.050 |
Why?
|
| Albumins | 1 | 2024 | 96 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2024 | 140 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 1556 | 0.050 |
Why?
|
| WT1 Proteins | 2 | 2013 | 24 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 43 | 0.050 |
Why?
|
| Feces | 1 | 2007 | 780 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 1723 | 0.050 |
Why?
|
| Phosphoproteins | 3 | 2012 | 443 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2024 | 309 | 0.050 |
Why?
|
| Homeostasis | 1 | 2007 | 730 | 0.050 |
Why?
|
| HLA-A2 Antigen | 2 | 2013 | 27 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 425 | 0.040 |
Why?
|
| Vaccinia virus | 1 | 2020 | 49 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2019 | 22 | 0.040 |
Why?
|
| Antigens, CD19 | 2 | 2011 | 182 | 0.040 |
Why?
|
| Alleles | 1 | 2004 | 1683 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2025 | 4725 | 0.040 |
Why?
|
| Remission Induction | 1 | 2020 | 307 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2011 | 879 | 0.040 |
Why?
|
| Phenotype | 2 | 2024 | 4545 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 126 | 0.030 |
Why?
|
| Time Factors | 3 | 2014 | 6455 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2018 | 412 | 0.030 |
Why?
|
| Gene Editing | 1 | 2019 | 212 | 0.030 |
Why?
|
| Vaccines, Attenuated | 1 | 2017 | 176 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 1292 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2018 | 714 | 0.030 |
Why?
|
| Injections, Intra-Arterial | 1 | 2014 | 18 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2014 | 47 | 0.030 |
Why?
|
| Aspergillus fumigatus | 1 | 2014 | 44 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 2014 | 59 | 0.030 |
Why?
|
| Balloon Occlusion | 1 | 2014 | 46 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 97 | 0.030 |
Why?
|
| Etanercept | 1 | 2014 | 47 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2014 | 77 | 0.030 |
Why?
|
| Aspergillosis | 1 | 2014 | 46 | 0.030 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 47 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2013 | 69 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 46 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 252 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 2013 | 19 | 0.030 |
Why?
|
| Myeloblastin | 1 | 2013 | 12 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2014 | 506 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 142 | 0.020 |
Why?
|
| Haplotypes | 1 | 2014 | 545 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 763 | 0.020 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 91 | 0.020 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 146 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 381 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 133 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 543 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2012 | 52 | 0.020 |
Why?
|
| Muromonab-CD3 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Carcinoma | 1 | 2014 | 300 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 303 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2014 | 795 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 470 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1570 | 0.020 |
Why?
|
| Telomerase | 1 | 2012 | 168 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 803 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 113 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 149 | 0.020 |
Why?
|
| eIF-2 Kinase | 1 | 2010 | 35 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2011 | 316 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2010 | 90 | 0.020 |
Why?
|
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2010 | 12 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2012 | 461 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2010 | 59 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2010 | 120 | 0.020 |
Why?
|
| Blood Cells | 1 | 2010 | 56 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 159 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2010 | 83 | 0.020 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 311 | 0.020 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2009 | 15 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 261 | 0.020 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2013 | 268 | 0.020 |
Why?
|
| Lentivirus | 1 | 2009 | 82 | 0.020 |
Why?
|
| Culture Media | 1 | 2009 | 183 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 558 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 402 | 0.020 |
Why?
|
| Eye | 1 | 2010 | 236 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2009 | 241 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 385 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2009 | 225 | 0.020 |
Why?
|
| MART-1 Antigen | 1 | 2007 | 14 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2007 | 16 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 999 | 0.020 |
Why?
|
| Neutrophils | 1 | 2009 | 359 | 0.020 |
Why?
|
| Liver | 1 | 2014 | 1815 | 0.020 |
Why?
|
| Melanoma | 1 | 2014 | 954 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2011 | 759 | 0.020 |
Why?
|
| Mothers | 1 | 2009 | 374 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1227 | 0.020 |
Why?
|
| Macrophages | 1 | 2010 | 693 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2005 | 56 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2007 | 388 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2005 | 201 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2687 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1458 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 2931 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2169 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 1305 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2004 | 174 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 3022 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 1153 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3619 | 0.010 |
Why?
|
| Apoptosis | 1 | 2009 | 1903 | 0.010 |
Why?
|
| Capsid | 1 | 2002 | 147 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2004 | 879 | 0.010 |
Why?
|
| United States | 1 | 2010 | 11627 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2004 | 8566 | 0.010 |
Why?
|